Such an argument is strengthened by the report from the group of Prof. Erik Sahai on the action of CAFs in conferring resistance to targeted therapies; resistance acquired by BRAF-mutated melanoma cells following PLX4720 [114]. The gene discussed is BRAF; the disease is melanoma.